HEPATIQ® -The Ultimate Liver Test™ - provides six indices of liver disease from a single scan including quantitative liver function.
GO BEYOND FIBROSIS STAGING
Liver tests currently being used estimate the extent of fibrosis, missing fibrosis compensation due to liver regeneration and increased blood flow to still functioning tissue.
HEPATIQ quantifies remaining liver function thus improving prediction of disease outcomes. To use a car analogy, other tests estimate the air in the gas tank. HEPATIQ measures the gas in the gas tank.
HEPATIQ is FDA cleared and the only quantitative liver function product on the market The scan is covered by the patient's insurance.
HEPATIQ® -THE ULTIMATE LIVER TEST®
The fed patient is injected with a low dose standard radioisotope - Tc99m sulfur colloid. A quick 20 minute SPECT scan of the liver is acquired. The HEPATIQ software analyzes these images to provide six indices of liver disease: quantitative liver function, steatosis/steatohepatitis, portal hypertension, alcoholic hepatitis, fibrosis stage and variceal size. It also provides a physiologic stage.
The HEPATIQ indices were proven to predict outcomes in the 8-year long multi-center HALT-C trial and outperformed all fibrosis tests. There are 28 publications on HEPATIQ and its clinical benefits.
When fibrosis tests reach the “what now?” point, turn to HEPATIQ for more insight into the health of the liver.
Brands: Biopsies, elastography and blood tests estimate liver fibrosis. Patient outcomes are determined by residual liver function, not the extent of fibrosis. This was established in the 8 year, prospective, multi-center, NIH sponsored HALT-C trial, which concluded that quantitative liver function may be more accurate than staging fibrosis in predicting clinical outcomes.[5,6] Subsequent research has further confirmed that function outperforms fibrosis in predicting outcomes. [12,13,16,17,21,22,24]
Products